Voucher equilibrium

Totting up supply, demand for Priority Review vouchers after Jazz-Spark deal

At $110 million, the sticker price on a Priority Review voucher from Spark Therapeutics Inc. (NASDAQ:ONCE) appears to be the new normal.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) purchased the voucher on April 30; Spark received it in December when FDA

Read the full 382 word article

User Sign In